Mersana Therapeutics Inc

Mersana Therapeutics — Investor Presentation (February 2019)

24 slides from Mersana Therapeutics's investor presentation, Feb 28, 2019

  1. Slide 1: Forward-looking statements

    This presentation contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking s

  2. Slide 2: Highly Experienced in Oncology and Business

    Highly Experienced in Oncology and Business David Mott Chairman Lawrence Alleva Director Willard Dere, M.D., FACP Director Andrew Hack, M.D, Ph.D. Director Kristen Hege, M.D. Director Anna Protopapas Director 3 Board of Directors Anna Protopapas Chief Executive Officer Eva Jack Chief Business Office

  3. Slide 3: XMT-1536 – Lead Asset in Proof-of-Concept Development

    XMT-1536 – Lead Asset in Proof-of-Concept Development Validated NaPi2b target First-in-class potential On track to achieve POC in 2019 Robust Discovery Effort Matching Target to Appropriate Platform • • • • Plan to disclose next clinical candidate in 2H 2019 Four Differentiated, Proprietary ADC Plat

  4. Slide 4: Dolaflexin Platform That Yielded XMT-1536

    Dolaflexin Platform That Yielded XMT-1536

  5. Slide 5: Designed to Expand Therapeutic Index vs Other ADC Platforms

    Designed to Expand Therapeutic Index vs Other ADC Platforms Significantly Higher Drug to Antibody Ratio (DAR) DolaLock is Designed to Enhance Efficacy and Tolerability Benefit of bystander effect for greater efficacy AF-HPA: Initial release after internalization in antigen expressing cell. Initial r

  6. Slide 6: XMT-1536

    XMT-1536 fficacy and Tolerability

  7. Slide 7: First-in-class Molecule, Target Expressed in Cancer Types with High Unmet Need

    First-in-class Molecule, Target Expressed in Cancer Types with High Unmet Medical Need Antibody • Validated Drug Target – – Transmembrane sodium-phosphate transporter Expressed in 87% of NSCLC adenocarcinoma, 96% of serous ovarian adenocarcinoma, 91% of papillary thyroid carcinoma1 Limited normal ti

  8. Slide 8: Lifastuzumab vedotin: Tolerability limited by vc-MMAE toxicity

    a Pre-clinical and clinical tolerability limited by vc-MMAE toxicity Lifastuzumab vedotin Genentech-developed ADC using Seattle Genetics vc-MMAE platform Appropriate target for ADC development but need for better tolerated platform No significant target-related toxicity in either ovarian or lung pat

  9. Slide 9: Target NaPi2b ADC Shows Favorable Outcome in Platinum Resistant Ovarian Cancer

    Target NaPi2b ADC Shows Favorable Outcome in Platinum Resistant Ovarian Cancer Compared to Standard of Care H-score high 10 Banerjee et al. Ann Oncol. 2018 Apr 1;29(4):917-923 Group ITT (n=95) NaPi2b 2/3+ (n=85) NaPi2b 3+ (n=70) NaPi2b median (n=43) Arm LIFA n=47 PLD n=48 LIFA n=42 PLD n=43 LIFA n=3

  10. Slide 10: Preclinical xenograft studies

    Studies OVCAR3 Ovarian Xenograft CTG-0852 NSCLC Patient Derived Xenograft c1441 c1270 c1342 11

  11. Slide 11: NaPi2b expression correlated with response

    Response • Proprietary research assay validated and used for retrospective evaluation of patients Only tumors with an H-score of >70 had a tumor response >50% • Preclinical data demonstrate NaPi2b expression highly correlated with response H-score 290* H-score 0 • ~60% of ovarian cancer patients est

  12. Slide 12: Ovarian cancer and NSCLC unmet need

    Areas of Docetaxel + Ramucirumab med PFS ~ 3–4.5 mos3 1Based on CancerMPact® Patient Metrics for US, Western Europe, and Japan, accessed in March 2018. 2https://cancerstatisticscenter.cancer.org/#!/ 3Hanna et al. JCO 2004 & Garon, Lancet 2014 & Pujade, JCO 2014 & Gordon, JCO 2001 & Rose, Gynecol Onc

  13. Slide 13: Target to Complete Dose Escalation and Initiate Dose Expansion Cohorts in 1H 2019

    Target to Complete Dose Escalation and Initiate Dose Expansion Cohorts in 1H 2019 2018 / 1H 2019 1H 2019 2H 2019 / 1H 2020 1H 2019 Anticipated Milestones Data Establish Recommended Go Forward Dose & Regimen Execute on Expansion Studies • Platinum-resistant ovarian cancer • NSCLC Adenocarcinoma in PD

  14. Slide 14: Current Clinical Study Data and Tolerability

    Data Current Clinical Study Data Show: Preclinical Studies Demonstrate Depletion of Kupffer Cells Results in Transient AST Elevations No observations of toxicities associated with other ADC platforms to date • No evidence of clinically relevant neutropenia, neuropathy, ocular toxicity or pneumonitis

  15. Slide 15: Platforms to Generate a Pipeline of ADCs

    Platforms to Generate a of ADCs

  16. Slide 16: Proprietary platforms to address broad unmet patient needs

    Create Dolasynthen Alkymer Immunosynthen Dolaflexin • High DAR • Precise DAR • Enables homogeneous ADCs • Designed to broaden addressable • Designed for localized and • Potential to increase efficacy against low expressing antigens harnessing of the immune system • Alkylating payload • DolaLock payl

  17. Slide 17: Dolasynthen: Critical Attributes Matched to Antibody and Target

    Critical Attributes Matched to Antibody and Target Aqueous solubility Charge Drug load per scaffold DolaLock AF-HPA Bioconjugation Site / Technology Antibody balance Anti-Tumor Efficacy Pharmacokinetics Tolerability Parameter Day Day Exposure (Day * ng/mL) Dolasynthen ADC 1 Dolasynthen ADC 2 Dolasyn

  18. Slide 18: Immunosynthen: STING ADC More Potent Than Free Agonist

    echnologies Payload Synthemer-STING ADC is >100x More Potent Than Free Agonist In Vitro Therapeutic Opportunity ADCs can ideally address the challenge of systemic delivery and tolerability of immunomodulatory payloads • • Specifically deliver STING agonists to targeted cells while increasing systemi

  19. Slide 19: Alkymer: DNA Alkylation Platform with Increased Therapeutic Index

    A DNA Alkylation Platform with Increased Therapeutic Index Colorectal Cancer • Some tumor types do not respond to auristatin • e.g. colorectal cancer, pancreatic cancer, certain hematological cancers (Resistant to Dolaflexin) 1200 1000 • DNA alkylators are active in auristatin1-resistant tumors exin

  20. Slide 20: Expanding Indications: Alkymer

    Colorectal Cancer (Resistant to Dolaflexin) —> Vehicle + Dolaflexin ADC —= Alkymer ADC Mean Tumor Volume (mm?) 0. 0 2 40 60 80 1 Days post treatment 2 mag dose * Dolaflexin employs a proprietary payload of the auristatin class Expanding Indications: Alkymer ADNA Alkylation Platform with Increased Th

  21. Slide 21: 2019 Milestones and Priorities

    • • • Select go forward dose and initiate expansion cohorts in 2Q 2019 Planning to report Phase 1 dose escalation data in 2Q 2019 Data from expansion cohorts in 2020 XMT-1536 • Planning to disclose next clinical candidate in 2H 2019 ADC Candidate • Initiation of Phase 1 Dose Escalation for our next

  22. Slide 22: $70.1M in cash extends runway into 2020

    $70.1M in cash* as of Q4 2018 extends cash runway into 2020 *Cash, cash equivalents and marketable securities as of December 31, 2018 23 Target Discovery Preclinical Development Phase 1 Preclinical/Clinical Pipeline: XMT-1536 NaPi2b 5T4 Multiple Undisclosed Discovery Pipeline: 1H 2020 IND Undisclose

  23. Slide 23: Unleashing the Targeted Power of ADCs

    Unleashing the Targeted Power of ADCs

  24. Slide 24: Unleashing the Targeted Power of ADCs

    Unleashing the Targeted Power of ADCs THERAPEUTICS

Mersana Therapeutics — Investor Presentation (February 2019) on 6ix